In this report, we determined the fit-for-purpose biomarker assay capabilities of this LC-MS assay in AD CSF using a standard curve of recombinant, intact 2N4R tau in artificial CSF matrix, including what is, to our knowledge, a first evaluation of parallelism for LC-MS tau quantification. This evidence concerns the gene MAPT and Alzheimer disease.